Patients with end-stage liver disease show sarcopenia, and preoperative sarcopenia is independently associated with patient mortality after liver transplantation. However, few studies have examined the relationship between perioperative loss of core muscle and patient mortality in living donor liver transplantation (LDLT). This study was performed to investigate the association between a perioperative decrease in the psoas muscle index (PMI) and patient mortality after LDLT. Adult patients (age 18 years) undergoing LDLT between January 2009 and December 2016 were classified into low-loss (>25th quartile) versus high-loss ( £ 25th quartile) groups according to PMI change between the day before surgery and postoperative day (POD) 7. Patient survival was compared between the 2 groups, and factors affecting survival were analyzed. The median (interquartile range) level of PMI change from the day before surgery to POD 7 was 24.8% (211.7%-1.2%). Although there was no preoperative difference in PMI between the low-loss and high-loss groups, patients with PMI change £ 211.7% showed poorer survival than those with PMI change >211.7% during the follow-up period. A PMI decrease £ 211.7% between the day before surgery and POD 7 is an independent predictor of patient mortality after LDLT. In addition, intraoperative packed red blood cell transfusion, graft fat percentage, and reoperation and infection after surgery were significantly associated with patient mortality. In conclusion, a PMI decrease £ 211.7% between the day before surgery and POD 7 is an independent predictor of patient mortality after LDLT. It is necessary to identify the factors responsible for the perioperative decrease in skeletal muscle mass and to ascertain if they are modifiable to improve patient survival after LDLT.
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Liver transplantation (LT) is a definitive therapy for endstage liver disease (ESLD). Because of donor graft shortage, living donor liver transplantation (LDLT) is accepted for treatment of patients with ESLD.
(1) The survival of patients undergoing LT is affected by poor recipient condition (ie, high Model for End-Stage Liver Disease [MELD] score) and inferior donor graft quality (ie, high donor risk index). (2) In comparison to LT, partial liver grafts are applied in recipients undergoing LDLT, and various factors, such as severe mismatch of graft recipient size and portal hyperperfusion, are related to patient and graft survival rate. (3, 4) Previous studies have focused on recovering allograft function and regeneration to ameliorate morbidity and mortality in LDLT. (5, 6) Patients with ESLD suffer from sarcopenia, and the development of sarcopenia is associated with poor natural course in clinical settings. The underlying pathway resulting in sarcopenia in ESLD patients is complex, and involves malnutrition, limited physical activity, hormonal alterations, and changes in the composition of the intestinal microbiome. (7) Although evidence of sarcopenia has accumulated in patients with ESLD, the impact of sarcopenia on postoperative outcome in an LT setting has been clarified. (8, 9) Independent of MELD score, which is an indicator of the severity of Abbreviations: ABGA, arterial blood gas analysis; BMI, body mass index; CI, confidence interval; CRRT, continuous renal replacement therapy; CT, computed tomography; EAD, early allograft dysfunction; ESLD, end-stage liver disease; HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range; LDLT, living donor liver transplantation; LT, liver transplantation; LVL, lumbar vertebra level; MELD, Model for End-Stage Liver Disease; MPAP, mean pulmonary artery pressure; OR, operating room; PaCO 2 , partial pressure of arterial carbon dioxide; PMA, psoas muscle area; PMI, psoas muscle index; POD, postoperative day; PRBC, packed red blood cell; SMM, skeletal muscle mass; SVRI, systemic vascular resistance index; WBC, white blood cell. hepatic decompensation and is used for allocation of liver grafts, preoperative sarcopenia itself was clearly associated with early prognosis after LT. (10) (11) (12) However, no study has evaluated the relationship between perioperative loss of core muscle and patient mortality in an LDLT setting.
This study evaluated the impact of a change in the psoas muscle index (PMI) between the preoperative value and that of postoperative day (POD) 7 on overall patient outcomes, including mortality, in LDLT. In addition, we describe changes in PMI throughout the first year after LDLT surgery.
Patients and Methods

STUDY POPULATION
A total of 473 adult patients (age 18 years) underwent LDLT at Seoul St. Mary's Hospital (Republic of Korea) between January 2009 and December 2016. Data from these patients were reviewed using the electronic medical records system in a retrospective study design, excluding defective records. The present study was approved by the institutional review board of Seoul St. Mary's Hospital ethics committee (KC17RIS I0001). The requirement for informed consent was waived due to the retrospective nature of the study.
SURGERY AND ANESTHESIA
The surgical processes and anesthetic care in LDLT have been described previously. (13) Briefly, the piggyback technique was applied using the right hepatic lobe with middle hepatic vein reconstruction.
Venovenous bypass was not performed. Balanced anesthesia was performed using a volatile agent (ie, desflurane), opioid drugs (ie, fentanyl and remifentanil), and muscular blockers (ie, rocuronium and cisatracurium) as appropriate.
IMMUNOSUPPRESSION AND NUTRITION
An immunosuppression regimen was implemented using 3 drugs, including a calcineurin inhibitor (ie, tacrolimus), mycophenolate mofetil, and prednisolone, based on the hospital LDLT protocol. The immunosuppressive drugs were gradually tapered after LDLT. An interleukin 2 competitor (ie, basiliximab) was administered before the surgery and on POD 4.
Without evidence of abdominal ileus, oral feeding commenced as follows: clear water on POD 1; watery gruel on POD 2; and rice gruel on POD 3. Thereafter, as the patient's condition improved, the amount of oral diet increased gradually, according to the hospital's specialized diet schedule for patients undergoing LDLT. In cases in which oral feeding was inappropriate postoperatively, due to poor mental status, mechanical ventilation, or surgical complications, experienced nutritionists calculated the patient's metabolic demands using the Harris-Benedict equation (14) and provided intravenous nutritional support.
PSOAS MUSCLE AREA MEASUREMENT AND PERIOPERATIVE CHANGE IN THE PMI
Patients scheduled for LDLT were examined for abnormal abdominal findings by computed tomography (CT) within 1 month before surgery. The patients were regularly evaluated for allograft state and both hepatic vessel and bile duct patency by CT on PODs 7 and 21, 6 months, and 1 year after surgery.
The CT images were analyzed retrospectively using PACS Viewer (INFINITT Healthcare Co., Ltd., Phillipsburg, NJ), and cross-sectional areas of both psoas muscles between the third and fourth lumbar vertebras were measured manually using the 2-dimensional module (Fig. 1) . Thereafter, the average of both psoas muscle areas (PMAs) was calculated and normalized by height squared (PMI 5 PMA/height squared).
We selected the PMI as a parameter of sarcopenia because previous studies suggested better accuracy of PMI for 1-year mortality than PMA/body surface area or skeletal muscle area index in the LT setting. (9, 15) The change in PMI from the day before surgery to POD 7 was calculated as follows:
½ðPMI on POD 7 -PMI on the day before surgeryÞ= PMI on the day before surgery3100 ð%Þ:
The study population was divided into 2 groups according to the interquartile range (IQR), ie, low-loss (>25th quartile) and high-loss (25th quartile) groups.
PERIOPERATIVE FACTORS OF RECIPIENTS AND DONORS
Preoperative findings included age, sex, body mass index (BMI), etiology of ESLD, comorbidities, history of abdominal surgery, MELD score, emergency surgery, complications of ESLD, transthoracic echocardiography, and laboratory findings. Intraoperative findings were surgical duration, continuous renal replacement therapy (CRRT), strong vasopressor, severe postreperfusion syndrome, average of vital signs, blood product transfusion, hourly fluid infusion and urine output, total amount of drug administration, and averages of laboratory and arterial blood gas analysis findings. Donor graft findings consisted of age, sex, BMI, diabetes mellitus, current smoker, percentage and type of steatosis, total ischemic time, and average of portal hemodynamics within PODs 1 and 3. Postoperative findings during hospital admission were hospital and intensive care unit (ICU) stays, fast-track extubation in the operating room (OR), incidence of dialysis, early allograft dysfunction (EAD), all-cause reoperation and infection, and relative liver graft volume.
POSTOPERATIVE OUTCOMES IN THE FOLLOW-UP PERIOD
Postoperative outcomes included acute cellular rejection, biliary complications, thrombosis, and de novo cancer occurrence. Investigation of overall patient survival was performed on the last outpatient visit during the follow-up period after LDLT.
STATISTICAL ANALYSIS
The perioperative factors were compared between the low-loss and high-loss groups using the MannWhitney U test and v 2 test. The normal distribution of the continuous data was evaluated by the ShapiroWilk test. Perioperative changes in PMI were analyzed using repeated-measures analysis of variance with Bonferroni post hoc test (1-sided test). The overall patient survival in the follow-up period was analyzed using the Kaplan-Meier test and compared between low-loss and high-loss groups using the log-rank test. The associations of perioperative variables, including PMI change within the day before surgery and POD 7, with overall patient mortality were evaluated by univariate and multivariate Cox regression analyses. Potentially significant determinants (P < 0.1) in univariate analysis were examined by multivariate analysis. The values are expressed as means 6 standard deviations, median (IQR), n (%), and hazard ratio (HR) and 95% confidence interval (CI). A P value < 0.05 was taken to indicate statistical significance. Statistical analyses were performed using SPSS for Windows (version 24; SPSS Inc., Chicago, IL) and MedCalc for Windows (version 11.0; MedCalc Software, Ostend, Belgium).
Results
For the study, 65 patients were excluded due to missing perioperative radiological findings regarding the psoas muscle (n 5 35), laboratory values (n 5 21), and vital sign parameters (n 5 9). Finally, 408 patients undergoing LDLT were evaluated in the present study.
The study cohort was predominantly male (70.1%), with a mean age of 52.0 6 8.9 years and mean BMI of 24.6 6 3.7 kg/m 2 . The etiologies for LDLT were as follows: hepatitis B virus (57.6%); alcohol abuse (20.1%); hepatitis C virus (7.6%); toxins and drugs (6.4%); autoimmune hepatitis (3.2%); hepatitis A virus (0.7%); and cryptogenic hepatitis (4.4%). Hepatocellular carcinoma was involved in 46.8% of the patients. The average MELD score was 16 6 1 points, and the mean follow-up period was 3.3 6 2.3 years. The median (IQR) level of PMI change from the day before surgery to POD 7 was 24.8% (211.7%-1.2%). The study population was divided into 2 groups: ie, low-loss (211.7%) and high-loss (<211.7%) groups. In the study population, differences in PMI between the low-loss and high-loss groups were observed on PODs 7 and 21; the median levels of PMI were significantly lower in the high-loss group than the low-loss group. In the overall and female cohorts, the median PMI was significantly higher in the low-loss group than in the high-loss group until 1 year after surgery. In the male cohort, the median PMI was higher in the low-loss group than in the high-loss group for 6 months after surgery ( Fig. 2 ; Supporting Table 1) .
With regard to preoperative findings, patients in the high-loss group had a higher median BMI, as well as higher median C-reactive protein and glucose levels, and a higher incidence of hepatorenal syndrome than those in the low-loss group, but the median ammonia levels were higher in the low-loss group than in the high-loss group (Table 1) . The intraoperative medians of prothrombin time, international normalized ratio, and activated partial thrombin time were greater in the high-loss group than the low-loss group, and the median antithrombin III level was lower in the highloss group than the low-loss group. The median partial pressure of arterial carbon dioxide (PaCO 2 ) retention was higher in the high-loss group than in the lowloss group. There were similarities between both groups in donor graft quality factors, such as donor age, graft steatosis, and portal hemodynamic patency (Table 2) .
With regard to postoperative findings during the in-hospital period, the median duration of ICU stay and mechanical ventilation were longer in the highloss group than in the low-loss group. Other than these findings, there were no significant differences related to graft regeneration or function between the 2 groups. Incidences of major complications, including acute cellular rejection, biliary problems, thrombosis, and de novo cancer development, were comparable between both groups throughout the follow-up period (Table  3) . Overall patient survival during the follow-up period was poorer in the high-loss group than in the low-loss group in the LDLT setting (Fig. 3) .
With regard to the associations between perioperative factors during in-hospital stay and overall patient mortality during the follow-up period, a decline in PMI (211.7%) from the day before surgery to POD 7, preoperative factors (ie, lung and kidney diseases, history of abdominal surgery, emergency surgery, severe encephalopathy, hematocrit, C-reactive protein, creatinine, and total bilirubin), intraoperative factors (ie, CRRT, central venous pressure, and total amounts of packed red blood cells [PRBCs] and fresh frozen plasma), donor graft factors (ie, male, BMI, steatosis percentage, and relative graft volume on the day before surgery and POD 21), average portal venous flow within POD 1 and 3, and postoperative factors (ie, hospital and ICU stays, fast-track extubation in OR, EAD development, all-cause reoperation, and infection) were potentially related to the overall patient mortality in univariate Cox analysis. In multivariate Cox analysis, the decrease in PMI (211.7%) was independently associated with overall patient mortality, together with intraoperative PRBC transfusion, reoperation, and infection after LDLT (Table 4) .
Discussion
The main finding of this study was that a decrease of PMI 211.7% between the day before surgery and POD 7 is an independent predictor of overall patient 
FIG. 2.
Comparison of the PMI between the low-loss and high-loss groups in (A) all patients, (B) males, and (C) females preoperatively, on PODs 7 and 21, and at 6 months and 1 year after LDLT. The box plots show the median (line in the middle of the box), IQR (box), 5th and 95th percentiles (whiskers), and outliers (dots). Statistical significance was set to *P < 0.05. 
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mortality after LDLT. Although there was no preoperative difference in PMI between low-loss and high-loss groups, the patients with PMI change of 211.7% had a poorer survival rate than those with PMI change of >211.7% during the follow-up period. In addition, the total amount of PRBC transfusion during surgery, graft fat percentage, and reoperation and infection after surgery were significantly associated with overall patient mortality in an LDLT setting. There have been a few studies regarding the association between preoperative sarcopenia and overall patient mortality in the LT setting. (8, 9, 12) In detail, central sarcopenia, using the cross-sectional PMA at the fourth lumbar vertebra level (LVL), was regarded as an indicator of patient frailty, and this parameter was closely related to mortality in LT. (8) Golse et al. (9) suggested that PMA and PMA/height squared at the intervertebral disk between the third and fourth LVLs presented better accuracy for 1-year survival after LT than other indices, and 1-and 5-year overall patient mortality rates were higher in the sarcopenic group than in the nonsarcopenic group after LT. In LDLT settings, preoperative sarcopenia, determined by measurement of skeletal muscle mass (SMM), was related to short-term mortality, and the SMM decreased postoperatively and did not reach the basal level within 1 year after surgery. (16) Another study showed that low PMI before LDLT was correlated with postoperative complications, including Clavien-Dindo classification (grade 3a) and 120-day mortality. (15) The present study suggested that the degree of decrease in PMI between the day before surgery and POD 7 influences overall patient mortality in the follow-up period after LDLT. In contrast to previous studies, (8, 9, 15, 16) we focused on the impact of perioperative decrease in SMM on patient survival after LDLT. Preoperative values of PMI were comparable between the low-loss and high-loss groups.
The underlying causes affecting the degree of reduction in PMI were not identified in the present study. On the basis of a previous report by Reisinger et al. (17) that the degree of SMM loss during neoadjuvant chemoradiotherapy was associated with patient mortality after esophageal cancer surgery, we speculated that patients with more frail features tend to lose a larger amount of core muscle than those with less frail characteristics under stressful stimuli, such as LDLT and ICU admission. As shown in Table 3 , the ICU stay and ventilator duration in the ICU were longer in the high-loss group than in the low-loss group. From these results, we suspect that a prolonged ICU stay and mechanical ventilation after LT are associated with postoperative changes in sarcopenia. Patients who have undergone LT should stay in the ICU, and a proportion of these patients inevitably require mechanical ventilation. However, meticulous and intensive perioperative care for weaning from ventilation may help shorten the ICU stay and duration of mechanical ventilation. To ascertain whether perioperative sarcopenic changes are modifiable, we must identify the factors that play a role in reducing muscle mass during the perioperative period and confirm that they truly are modifiable.
Considering other independent factors for overall patient mortality in our study, the more PRBCs transfused during the surgery, the poorer the overall patient survival. This supported the observation by Ramos et al. (18) that intraoperative transfusion of 3 units of PRBCs was associated with an extended hospital stay NOTE: Values are expressed as n (%) and median (IQR).
and PRBC transfusion of 6 units resulted in poor survival in LT. Another study suggested that the 1-year survival rate was reduced in proportion to increasing transfusion of PRBCs during LT. (19) Second, graft steatosis was deemed to be an independent determinant of overall patient mortality in this study. Many studies reported to date suggested favorable outcomes with the use of marginal grafts from mild-to-moderate steatosis compared with no graft steatosis in LDLT. (20, 21) Severely fatty grafts were not recommended for transplantation due to adverse effects on graft survival in LT settings. (22) Contrasting with previous studies, (20) (21) (22) our data suggested that less fatty grafts were associated with better prognosis after LDLT, even in patients with mild-to-moderate steatosis. Third, all-cause reoperation after LDLT was independently associated with poor overall patient survival in our study. This agreed with a previous study indicating that patients with early relaparotomy showed poorer graft survival than those without early reoperation, and preoperative high MELD score and substantial intraoperative hemorrhage were related to graft mortality in patients with early relaparotomy in LDLT. (23) Fourth, all-cause infection after LDLT was associated directly with poor overall patient survival in the present study. As a result of immunosuppressive drug administration after surgery, the patients were vulnerable to new or latent activation of infection, and the infective activation was the main cause of poor postoperative outcome in LT settings. (24) We investigated the association between perioperative loss (from preoperative day to POD 7) of the PMI and patient survival in LDLT. To date, no cutoff value for muscle loss affecting the survival of critically ill patients has been generally accepted. We intended to compare survival rates between groups with severely and moderately reduced PMI. Therefore, we chose the lowest quartile as the threshold and classified patients into 2 groups: low-loss (above the lowest quartile) and high-loss (the lowest quartile) groups.
This study had several limitations. First, we applied PMI as an indicator to measure sarcopenic changes from the day before surgery to POD 7. Although the psoas muscle is one of the major core muscles, decreased psoas muscle mass does not entirely represent the development of overall sarcopenia, and we could not differentiate the psoas muscle itself from intermuscular fatty tissue. A recent study suggested that psoas muscle volume was more closely associated with postoperative outcome than its area in LDLT. (25) However, because we focused on dynamic changes in PMI based on the preoperative values, this would offset the above shortcoming of static PMI measurement. Second, we could not quantitatively evaluate perioperative status of nutrition and physical activity due to the retrospective study design. Because these conditions could affect psoas muscle mass, further evaluation is required. Third, we were not able to specify the independent factors affecting reduction of perioperative psoas muscle mass due to the study design. Future studies related to these factors will be helpful to attenuate perioperative core muscle loss and improve patient survival in LDLT. Finally, the analysis of serial CT images of all patients who underwent LDLT was not possible because some patients did not undergo CT due to serious medical conditions. Therefore, selection bias in the study population cannot be ruled out entirely, and the data should be interpreted with caution.
In conclusion, a greater degree of core muscle mass loss through LDLT and postoperative recovery is associated with poorer overall patient survival rate. The present study suggested that PMI change of 211.7% between the day before surgery and POD 7 could be used as an independent predictor of overall patient
Comparison of overall patient survival rates between the low-loss and high-loss groups in terms of PMIs in the follow-up period after LDLT. Overall patient survival was significantly different between the 2 groups (P 5 0.04). The 1-, 3-, and 5-year survival rates were 91%, 88%, and 87% in the low-loss group, and 92%, 82%, and 73% in the high-loss group, respectively. mortality in the follow-up period after LDLT. However, the underlying mechanism has not been clarified. Future studies are required to identify the factors responsible for perioperative sarcopenic changes, and to verify whether these changes are modifiable in patients undergoing LDLT. 
